Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
2,649
Stocks News & Analysis
stocks
Why Morningstar thinks Anthropic is worth $1.7 trillion
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,267.80 | 104.40 | 1.14% |
| CAC 40 | 8,297.19 | 63.90 | 0.78% |
| DAX 40 | 26,455.53 | 188.34 | 0.72% |
| Dow JONES (US) | 52,052.34 | 337.41 | -0.64% |
| FTSE 100 | 10,780.47 | 2.40 | -0.02% |
| HKSE | 24,557.04 | 108.09 | 0.44% |
| NASDAQ | 25,085.18 | 167.96 | -0.67% |
| Nikkei 225 | 60,459.58 | 1,684.08 | 2.87% |
| NZX 50 Index | 14,167.41 | 193.79 | 1.39% |
| S&P 500 | 7,504.71 | 45.23 | -0.60% |
| S&P/ASX 200 | 9,129.00 | 99.30 | 1.10% |
| SSE Composite Index | 3,663.72 | 2.93 | 0.08% |